Profile: Curis Inc (CRIS.OQ)
4.07USD
1 Aug 2013
$-0.08 (-1.93%)
$4.15
$4.18
$4.20
$4.00
57,262
117,132
$4.89
$2.67
Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly owned member of the Roche Group. The lead drug candidate being developed under this program is Erivedge, a orally-administered small molecule Hedgehog pathway inhibitor, which is also known as vismodegib, GDC-0449 and RG3616.
Hedgehog Pathway Inhibitor Program (Erivedge)
The Hedgehog pathway is normally active during embryonic development and regulates tissue and organ formation by directly promoting cell division in specific cell types, and by activating other secondary signaling pathways that control the synthesis of growth factors and angiogenic (blood vessel-forming) factors. Genentech and Roche are responsible for the clinical development and commercialization of Erivedge and are conducting a Phase II clinical trial of GDC-0449 in operable BCC that was initiated in 2010. Genentech completed two Phase II clinical trials of Erivedge, including in advanced ovarian cancer and metastatic colorectal cancer.
Targeted Cancer Programs
In this program, the Company focuses on developing small molecule single-agent drug candidates that target one or more molecular components within the network of signaling pathways associated with certain cancers. CUDC-101 is the first compound drug candidate selected from its portfolio of network-targeted cancer programs. CUDC-101 simultaneously inhibits both EGFR and Her2 at the receptor level while blocking downstream HDAC inhibition within the cancer cells. Despite the existence of other multi-targeted inhibitors, CUDC-101 enables a synergistic attack on multiple nodes or points in the overall pathway network that are used by tumors to survive, grow, and invade surrounding tissue. In October 2011, the Company completed a Phase Ib expansion trial to test CUDC-101 in 46 patients with specific tumor types, including breast, gastric, head and neck, liver and non-small cell lung cancers.
In January 2011, the Company selected development candidate CUDC-907, an orally bioavailable, network-targeted small molecule that is designed to inhibit HDAC and phosphatidylinositol-3-kinase (PI3K). CUDC-907 also inhibits tumor growth in preclinical xenograft models of hematology cancers and solid tumors with K-RAS mutations. The Company’s development candidate under collaboration is Debio 0932 (formerly CUDC-305), an Heat shock protein 90 (Hsp90) inhibitor that Curis licensed to Debiopharm Group in August 2009 and that is in Phase Ib clinical testing.
The Company competes with Infinity Pharmaceuticals, Inc., Exelixis, Inc., Pfizer Inc., Novartis International AG, Millennium Pharmaceuticals, Bristol-Myers Squibb Company, Astex Therapeutics Ltd., Myriad Pharmaceuticals Inc., Kyowa Hakko Kirin Co, Ltd., Daiichi Sankyo and Synta Pharmaceuticals Corp.
Company Address
Curis Inc
4 Maguire Road
LEXINGTON MA 02421
P: +1617.5036500
F: +1617.5036501
Company Web Links
| Name | Compensation |
|---|---|
James McNab |
-- |
Ali Fattaey |
-- |
Daniel Passeri |
841,240 |
Michael Gray |
610,700 |
Mani Mohindru |
-- |

